Literature DB >> 17893119

Mucosal endocrine cell micronests and single endocrine cells following neo-adjuvant therapy for adenocarcinoma of the distal oesophagus and oesophagogastric junction.

Colin J R Stewart1, Simon Hillery.   

Abstract

AIMS: To determine the frequency of endocrine cell micronests (ECM) and single endocrine cells (SEC) within the glandular mucosa of the distal oesophagus and oesophagogastric junction (OGJ) following neo-adjuvant therapy for adenocarcinoma.
METHODS: The resection specimens from 11 patients with adenocarcinoma of the distal oesophagus or OGJ who had undergone preoperative chemotherapy or chemoradiotherapy (CRT) were reviewed and stained immunohistochemically for cytokeratin and chromogranin. The presence of ECM and/or SEC within the mucosa adjacent to the tumour was noted, and the results correlated with the extent of tumour regression. The corresponding pretreatment endoscopic biopsy specimens were reviewed in 6 cases, and the results were also compared to 10 tumour resections from patients with no history of neo-adjuvant treatment.
RESULTS: ECM and/or SEC were identified in 8/11 resection specimens after chemotherapy or CRT. The endocrine cells were typically located within the deep lamina propria or muscularis mucosae and were associated with varying degrees of glandular atrophy and inflammation. The appearances were most consistent with endocrine cell preservation (pseudo-hyperplasia) following treatment. Isolated endocrine elements were not seen in the pretreatment biopsy specimens, while rare SEC without ECM were identified in only 2/10 control resection specimens.
CONCLUSIONS: Endocrine cell pseudo-hyperplasia may be seen within atrophic glandular mucosa following neo-adjuvant therapy of distal oesophageal/OGJ adenocarcinomas. The changes are analogous to those seen in chronic atrophic gastritis and should not be misinterpreted as those of residual tumour.

Entities:  

Mesh:

Year:  2007        PMID: 17893119      PMCID: PMC2095480          DOI: 10.1136/jcp.2007.047449

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  29 in total

1.  Prevalence and prognostic significance of neuroendocrine cells in esophageal adenocarcinoma.

Authors:  K Hamilton; A Chiappori; S Olson; J Sawyers; D Johnson; K Washington
Journal:  Mod Pathol       Date:  2000-05       Impact factor: 7.842

2.  Gastric dysplasia-like epithelial atypia associated with chemoradiotherapy for esophageal cancer: a clinicopathologic and immunohistochemical study of 15 cases.

Authors:  T P Brien; F A Farraye; R D Odze
Journal:  Mod Pathol       Date:  2001-05       Impact factor: 7.842

3.  The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and esophagogastric junction after preoperative chemoradiation.

Authors:  Kim L Wang; Qinghua Yang; Karen R Cleary; Stephen G Swisher; Arlene M Correa; Ritsuko Komaki; Jaffer A Ajani; Asif Rashid; Stanley R Hamilton; Tsung-Teh Wu
Journal:  Cancer       Date:  2006-10-01       Impact factor: 6.860

Review 4.  Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment.

Authors:  Steven R DeMeester
Journal:  Ann Surg Oncol       Date:  2006-01-01       Impact factor: 5.344

5.  Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome.

Authors:  Tsung-Teh Wu; Lucian R Chirieac; Susan C Abraham; Alyssa M Krasinskas; Huamin Wang; Asif Rashid; Arlene M Correa; Wayne L Hofstetter; Jaffer A Ajani; Stephen G Swisher
Journal:  Am J Surg Pathol       Date:  2007-01       Impact factor: 6.394

Review 6.  Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction.

Authors:  Sjoerd M Lagarde; Fiebo J W ten Kate; Johannes B Reitsma; Olivier R C Busch; J Jan B van Lanschot
Journal:  J Clin Oncol       Date:  2006-09-10       Impact factor: 44.544

7.  Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.

Authors:  Paul M Schneider; Stephan E Baldus; Ralf Metzger; Martin Kocher; Rudolf Bongartz; Elfriede Bollschweiler; Hartmut Schaefer; Juergen Thiele; Hans P Dienes; Rolf P Mueller; Arnulf H Hoelscher
Journal:  Ann Surg       Date:  2005-11       Impact factor: 12.969

8.  Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response.

Authors:  Pooja Rohatgi; Stephen G Swisher; Arlene M Correa; Tsung-T Wu; Zhongxing Liao; Ritsuko Komaki; Garrett L Walsh; Ara A Vaporciyan; David C Rice; Jack A Roth; Jaffer A Ajani
Journal:  Cancer       Date:  2005-12-01       Impact factor: 6.860

9.  Rectal adenocarcinoma with oncocytic features: possible relationship with preoperative chemoradiotherapy.

Authors:  M Rouzbahman; S Serra; R Chetty
Journal:  J Clin Pathol       Date:  2006-02-07       Impact factor: 3.411

10.  Prognostic value of tumour regression grading and depth of neoplastic infiltration within the perirectal fat after combined neoadjuvant chemo-radiotherapy and surgery for rectal cancer.

Authors:  E Benzoni; D Intersimone; G Terrosu; V Bresadola; A Cojutti; F Cerato; C Avellini
Journal:  J Clin Pathol       Date:  2006-03-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.